In an interview with Targeted Oncology, Pavlos Msaouel, MD, PhD, at The University of Texas MD Anderson Cancer Center ...
The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a ...
Dr. Nooka presents a comprehensive treatment algorithm for 100 patients with relapsed multiple myeloma, providing clear ...
Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast ...
The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down the landmark findings, and explains why this trial is now considered ...
In November 2025, the FDA granted priority review to the new drug application (NDA) of sonrotoclax (BGB-11417), an ...
CB-011, an allogeneic CAR T product, received RMAT designation as treatment for multiple myeloma based on strong dose ...
The conversation highlights how AI is redefining what it means to be a medical expert. Pattern Recognition: Modern expertise ...
Dr. Nooka presents a case-based approach to treatment selection using a 50-year-old woman with relapsed/refractory multiple myeloma who progressed after 15 months on lenalidomide maintenance following ...
With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses ...
In this segment focused on advanced renal cell carcinoma, Dr. Geynisman shifts the discussion to patients with intermediate ...
The FDA has granted a priority review to a new drug application (NDA) for lirafugratinib, a highly selective oral FGFR2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results